Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE40.9400
- TODAY'S CHANGE (%)-0.5600 (-1.3494%)
- Bid / Lots40.9000/ 2
- Ask / Lots40.9700/ 4
- Open / Previous Close41.2700 / 41.5000
- Day Range
- 52 Week Range
- Volume81,256
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 8398 | 41.335 |
| 09:34 ET | 100 | 41.23 |
| 09:36 ET | 200 | 41.325 |
| 09:38 ET | 3826 | 41.27 |
| 09:39 ET | 1100 | 41.2 |
| 09:41 ET | 1500 | 41.32 |
| 09:43 ET | 100 | 41.32 |
| 09:45 ET | 600 | 41.3 |
| 09:48 ET | 1000 | 41.23 |
| 09:50 ET | 498 | 41.21 |
| 09:52 ET | 100 | 41.24 |
| 09:54 ET | 400 | 41.26 |
| 09:56 ET | 927 | 41.22 |
| 09:57 ET | 1650 | 41.145 |
| 09:59 ET | 915 | 41.03 |
| 10:01 ET | 1532 | 40.985 |
| 10:03 ET | 1700 | 41.065 |
| 10:06 ET | 1109 | 41.01 |
| 10:08 ET | 2924 | 40.99 |
| 10:10 ET | 3139 | 40.882 |
| 10:12 ET | 1256 | 40.96 |
| 10:14 ET | 400 | 40.98 |
| 10:15 ET | 700 | 40.945 |
| 10:17 ET | 1862 | 40.96 |
| 10:19 ET | 900 | 40.95 |
| 10:21 ET | 1200 | 40.985 |
| 10:24 ET | 800 | 41.055 |
| 10:26 ET | 600 | 41.1 |
| 10:28 ET | 1224 | 41.04 |
| 10:30 ET | 575 | 41.02 |
| 10:32 ET | 1100 | 40.96 |
| 10:33 ET | 800 | 40.94 |
| 10:35 ET | 1495 | 40.85 |
| 10:37 ET | 836 | 40.77 |
| 10:39 ET | 757 | 40.78 |
| 10:42 ET | 2745 | 40.8 |
| 10:44 ET | 400 | 40.76 |
| 10:46 ET | 1175 | 40.82 |
| 10:50 ET | 200 | 40.94 |
Jun 3, 2024
DJ Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 5:39AM ET on Monday Jun 03, 2024 by Dow Jones
5:39AM ET on Monday Jun 03, 2024 by Dow Jones
May 31, 2024
May 28, 2024
Ionis to hold donidalorsen Phase 3 data webcast, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 23, 2024
May 16, 2024
DJ Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk, from 11:52AM ET on Thursday May 16, 2024 by Dow Jones
11:52AM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 5.8B | -15.3x | --- |
Halozyme Therapeutics Inc | 6.4B | 20.5x | --- |
Apellis Pharmaceuticals Inc | 5.2B | -12.3x | --- |
CRISPR Therapeutics AG | 5.3B | -24.8x | --- |
Guardant Health Inc | 3.7B | -8.1x | --- |
Azenta Inc | 3.0B | -20.1x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Contact Information
- Headquarters
- 2855 Gazelle CourtCARLSBAD, CA, United States 92010
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Executive Vice President, Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.8B |
|---|---|
Revenue (TTM) | $776.6M |
Shares Outstanding | 146.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $-2.67 |
Book Value | $2.68 |
P/E Ratio | -15.3x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -48.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
